文献速递肝病

减轻年龄对FIB-4筛查MASLD相关肝纤维化影响的策略评估

Assessing Strategies to Mitigate the Effect of Age When Using Fibrosis-4 Index to Screen for Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Liver Fibrosis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-09-10

该研究在2个独立MASLD队列(n=604和n=334)中比较标准FIB-4与4种年龄调整策略检测≥F2、≥F3和肝硬化的性能,并以磁共振弹性成像或肝活检为参考。所有策略的AUROC相似(0.76-0.81),FIB-3在年龄极端人群中显示平衡的敏感性与特异性。

要点

  • 标准FIB-4与4种年龄调整策略对≥F2或≥F3的AUROC相似(0.76-0.81)。
  • FIB-3(去除年龄)在<35岁和≥65岁人群中敏感性与特异性平衡。
  • 各策略的阳性预测值和阴性预测值无重大影响。

核心结论

  • 在MASLD成人中,限制年龄对FIB-4影响的策略维持了与标准FIB-4相当的判别能力。
  • 不依赖年龄的FIB-3在不同年龄层维持诊断准确性,支持在初级保健筛查人群中进一步前瞻性评估。

研究设计与样本

  • 使用2个独立MASLD队列评估FIB-4及4种替代策略检测≥F2、≥F3和肝硬化。
  • 队列1(n=604)以磁共振弹性成像为参考,队列2(n=334)以肝活检为参考。
  • 利用2017至2020年NHANES在未选择队列中评估策略。

主要发现

  • 938名参与者(年龄54±12岁,50%女性,BMI 34.7±6.7 kg/m2,42%糖尿病)中20%有≥F2,13%有≥F3,3%有肝硬化。
  • 所有策略检测≥F2或≥F3的AUROC相似:vs磁共振弹性成像为0.76-0.78,vs肝活检为0.77-0.81。
  • 基于预设或计算界值,策略间敏感性和特异性有差异,但对阳性预测值和阴性预测值无重大影响。
  • FIB-3在年龄极端(<35岁和≥65岁)显示平衡的敏感性-特异性权衡。

关键数值与推荐

  • 标准FIB-4使用1.3作为界值。
  • 年龄调整策略包括:≥65岁使用FIB-4界值2.0;FIB-3(从FIB-4公式中去除年龄);capped FIB-4(<35岁或>65岁分别以35或65岁作为年龄输入);log-transformed FIB-4(使用年龄的自然对数)。

临床怎么用

  • 在MASLD成人筛查肝纤维化时,可考虑使用FIB-3等年龄调整策略以减少年龄对FIB-4的影响。
  • FIB-3在年轻和老年人群中维持诊断准确性,可能适合初级保健筛查场景。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Fibrosis-4 (FIB-4) is recommended to screen for liver fibrosis in at-risk individuals, but its performance is limited at extremes of age. This study compared different strategies to limit the effect of age on FIB-4. METHODS: Using 2 independent metabolic dysfunction-associated steatotic liver disease cohorts, we assessed FIB-4 and 4 alternative strategies to detect ≥ F2, ≥F3, and cirrhosis. The strategies assessed were: (1) standard FIB-4 with 1.3 as cutoff; (2) FIB-4, but using a cutoff of 2.0 for ≥65 years; (3) FIB-3 where age was removed from the FIB-4 formula; (4) capped FIB-4 (where 35 or 65 years were used as age inputs in individuals <35 or >65 years, respectively), and (5) log-transformed FIB-4, where the natural logarithm of age was used. Magnetic resonance elastography was used as reference in cohort #1 (n = 604), and liver biopsy in cohort #2 (n = 334). The National Health and Nutrition Examination Survey, 2017 to 2020, was used to assess the strategies in an unselected cohort. RESULTS: Among 938 participants (age, 54 ± 12 years; 50% female; body mass index, 34.7 ± 6.7 kg/m2; 42% with diabetes), 20% had ≥ F2, 13% ≥F3, and 3% cirrhosis. All strategies had similar areas under the receiver operating characteristic curve (AUROCs) for detection of ≥F2 or ≥ F3 vs magnetic resonance elastography (AUROCs, 0.76-0.78) or liver biopsy (AUROCs, 0.77-0.81). Based on prespecified or calculated cutoff points, strategies differed in sensitivity and specificity, but without major impact on positive predictive value and negative predictive value. FIB-3 demonstrated a balanced sensitivity-specificity trade-off at age extremes (<35 and ≥65 year old individuals). CONCLUSIONS: In adults with metabolic dysfunction-associated steatotic liver disease, strategies to limit age effect on FIB-4 maintained discrimination relative to standard FIB-4. An age-independent approach (FIB-3) maintains diagnostic accuracy across diverse age strata, supporting further prospective evaluation in primary care screening populations.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Nammi J, Southall W, Huynh K, et al. Assessing Strategies to Mitigate the Effect of Age When Using Fibrosis-4 Index to Screen for Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Liver Fibrosis. Clin Gastroenterol Hepatol. 2026. PMID: 42722220. doi:10.1016/j.cgh.2026.09.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。